A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer

<div>Representative CD8 T-cell region of Cen-se maps in (a) a patient with non-cold type, and (b) a patient with cold type. (c) The mean and standard error of effector memory and terminal effector CD8 T-cell percentage in 10 patients’ blood sample. The proportion of effector memory CD8 T-cells (T8 em, the blue region in Figures <a href="../fig2/#a">2(a)</a> and <a href="../fig2/#b">2(b)</a>) was higher in patients with cold type than that in patients with non-cold type. Meanwhile, the proportion of terminal effector CD8 T-cells (T8 te, the yellow region in Figures <a href="../fig2/#a">2(a)</a> and <a href="../fig2/#b">2(b)</a>) was higher in patients with non-cold type than that in patients with cold type.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer 

Figure 2 | A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer 